4 European Projects Found
Searched on 125080 European Projects
FINISHED
REgenerative Stem cell therapy for STroke in Europe (RESSTORE)
Start date: Sep 1, 2015, End date: Aug 31, 2020,
Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke ...
Read Project
29
Partners Participants
FINISHED
Secondary prEvention of CardiovascUlaR disease in the Elderly trial (SECURE)
Start date: May 1, 2015, End date: Apr 30, 2020,
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adhe ...
Read Project
13
Partners Participants
FINISHED
Combatting Bacterial Resistance in Europe (COMBACTE-NET)
Start date: Jan 1, 2013, End date: Dec 31, 2019,
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are aro ...
Read Project
38
Partners Participants
FINISHED
International study for treatment of childhood relapsed ALL 2010 with standard therapy, systematic integration of new agents, and establishment of standardized diagnostic and research (INTREALL)
Start date: Oct 1, 2011, End date: Sep 30, 2016,
Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood cancer. Given the rarity of the disease, only a large international cooperative group can recruit sufficient patients for prospective studies with specific questions in biologic subgroups. Under the umbrella of the I-BFM SG all relevant mainly European study ...
Read Project
